NWBO Northwest Biotherapeutics, Inc. Paradigmenwechsel in Biotech - Phase 3 results
eröffnet am 25.05.20 16:55:53 von
neuester Beitrag 08.05.24 23:51:31 von
neuester Beitrag 08.05.24 23:51:31 von
Beiträge: 1.199
ID: 1.325.306
ID: 1.325.306
Aufrufe heute: 0
Gesamt: 80.053
Gesamt: 80.053
Aktive User: 0
ISIN: US66737P6007 · WKN: A1J5EY · Symbol: NWBO
0,4800
USD
-1,91 %
-0,0094 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Neuigkeiten
13.10.23 · PR Newswire (engl.) |
25.09.23 · Accesswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
2,4500 | +30,32 | |
2,7100 | +22,62 | |
1,4500 | +22,36 | |
2,7500 | +22,22 | |
5,5500 | +16,60 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5900 | -18,04 | |
3,3100 | -20,62 | |
2,2000 | -21,43 | |
5,0000 | -37,34 | |
0,9700 | -71,47 |
Beitrag zu dieser Diskussion schreiben
Die wohl beste zusammenfassung:
OS: Placebo: 7.7 Monate poly-ICLC: 52.5 Monate
https://www.nature.com/articles/s41467-024-48073-y
OS: Placebo: 7.7 Monate poly-ICLC: 52.5 Monate
https://www.nature.com/articles/s41467-024-48073-y
nature artikel heute veröffentlicht
phase2 dcvax mit und ohne poly iclc agonist
seit 2014 gehört polyIclc von oncovir zur dcvax formel dazu. der nature artikel zeigt duetlich, das diese combi noch viel bessere resultate bring als dcvax "alleine".
In den Ergebnisse der ph3 studie, die ja noch länger andauerte, ist dies noch nicht enthalten!!!!
https://www.nature.com/articles/s41467-024-48073-y#:~:text=W…
phase2 dcvax mit und ohne poly iclc agonist
seit 2014 gehört polyIclc von oncovir zur dcvax formel dazu. der nature artikel zeigt duetlich, das diese combi noch viel bessere resultate bring als dcvax "alleine".
In den Ergebnisse der ph3 studie, die ja noch länger andauerte, ist dies noch nicht enthalten!!!!
https://www.nature.com/articles/s41467-024-48073-y#:~:text=W…
alles interessant
ab 30 Minuten interessanter
ab 30 Minuten interessanter
https://www.otcmarkets.com/filing/html?id=17505671&guid=hdQ-…
hierfür (unter anderem) ein weiteres darlehen über 11 Million.
wieder von streeterville, ein nicht ganz so seriöses unternehmen 🥷
hierfür (unter anderem) ein weiteres darlehen über 11 Million.
wieder von streeterville, ein nicht ganz so seriöses unternehmen 🥷
jetzt sind wir schon im mai/24. Sieht so aus als ob flashwork approval kommt zusammen mit dcvax approval in the uk ! ?
wer lesen möchte . . . ? eine interessante zusammenfassung
("etwas" ausführlicher als meine mehrmals VERfassten,
die meist nur einen kürzeren zeitraum UMfassten)
- just in english von einem dude
namens danish dude aus ihub:
Everything below are facts
Data lock happened
MIA approval happened
Advent has ramped up from 14 to around 100 employees
A production unit of Flaskworks Eden is now being made
NWBO has filed for MAA approval
MHRA has been extraordinary funded with $10M for 2 years, with the purpose of also getting cancer vaccines faster to patients
British politicians have urged MHRA to approve and NICE to reimburse in the Pathway to a Cure report
Two combo trials are being run at UCLA, with DCvax-L and poly-iclc and Keytruda. Another one in preparation that will also include DCVax + Keytruda + CSF-1R Inhibitor Pexidartinib (PLX-3397)
ATL-DC in the two UCLA combo trial ARE beyond all doubt - DCVax-L
There's a lawsuit against 7 market makers. No deal announced. No costs shown in SEC filings. Cohen and Milstein usually take these cases on contingency. Thus, it is rational to assume it HAS been taken on contingency, since this is a HUGE lawsuit.
"In January 2016 Black became an independent director of NWBO to investigate the market manipulation of the company's stock by the hedge fund "wolfpack". The wolfpack and others use naked shorting of stock to drive promising young biotechs toward bankruptcy or to the point where they need to raise capital at extremely low valuations from the wolfpack themselves", as was stated in an Alchetron news article.
NWBO stated in a PR
"It is exciting to see the potential of the DCVax personalized immune therapies being developed by NW Bio for a wide range of cancers. I look forward to utilizing my expertise in helping the Company protect its technology and operations."
So when the lawsuit came 2022, and the plaintiff say they have +6 years of evidence against MM and their spoofing, it is rational to believe, THAT was Cofer Blacks job.
A Nature journal preprint is on its way regarding the results of the DCvax-L and poly-iclc trial.
MHRA stated about confirmatory efficacy trial
Although each biosimilar development needs to be evaluated on a case by case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach.
FDA states in its guidance documents outline how biosimilars may be approved based on pharmacokinetic (PK) data and PD biomarker data without a comparative clinical efficacy study. Reliance on PK and PD data allows for shorter and less costly clinical studies that can often be conducted in healthy participants
Let's look at facts about companies Revimmune SAS, Ltd, Inc
Linda Powers director in US and UK and in full control. Revimmune trials with Interleukin-7 back more than a decade gets PR'ed as Revimmune Inc. http://Revimmune.com say Maryland Bethesda is head office. Head office address is same address as Northwest Bio Inc and Toucan Capital. Revimmune is assignee on combo patent from 2014. Interleukin-7 also called IL-7 is in many claims on the combo patent. Before 2012 it was called CYT-107 after the company Cytheris. Mac Cheever was working with it. He joined NWBO SAB in 2016.
Revimmune Ltd dormant company but just been confirmed, that "its intended future activities are lawful" meaning ...
[Suppressed Image]
Industry Codes used
[Suppressed Image]
$NWBO is in control of NWBO Limited since January 19th. 2024. Linda Powers ASSIGNED control to NWBO Inc.
3 months ago!!!
Northwest Biotherapeutics Limited and Revimmune Inc shares a funny same address.
J Kelly Ganjei from AmplifyBio and being on the combo patent and Philippe Pire from Advent Bioservices are "attached".
[Suppressed Image]
[Suppressed Image]
Linda Powers and Mark Lowdell ownes a company called Novamune LTD.
[Suppressed Image]
[Suppressed Image]
On April 2 a compulsory strike-off was sent and supposedly Novamune had two months to respond. On April 25, the government issued a formal notice already on discontinuing the strike-off notice.
Mark Lowdell is a consultant to Inmune Bio. Turns out he is ALSO on the SAB board of NWBO.
[Suppressed Image]
But NWBO have not disclosed him being so!
J Kelly Ganjei, the guy having worked for Linda Powers at Toucan, who is on the combo patent, who is CEO of AmplifyBio is also on the board of Inmune Bio
Phil Parry who have been head of engineering at Roche and Autolomous just hired at Advent Bioservice. A step down or step up?
noch ausführlicher:
https://investorshub.advfn.com/boards/read_msg.aspx?message_…
("etwas" ausführlicher als meine mehrmals VERfassten,
die meist nur einen kürzeren zeitraum UMfassten)
- just in english von einem dude
namens danish dude aus ihub:
Everything below are facts
Data lock happened
MIA approval happened
Advent has ramped up from 14 to around 100 employees
A production unit of Flaskworks Eden is now being made
NWBO has filed for MAA approval
MHRA has been extraordinary funded with $10M for 2 years, with the purpose of also getting cancer vaccines faster to patients
British politicians have urged MHRA to approve and NICE to reimburse in the Pathway to a Cure report
Two combo trials are being run at UCLA, with DCvax-L and poly-iclc and Keytruda. Another one in preparation that will also include DCVax + Keytruda + CSF-1R Inhibitor Pexidartinib (PLX-3397)
ATL-DC in the two UCLA combo trial ARE beyond all doubt - DCVax-L
There's a lawsuit against 7 market makers. No deal announced. No costs shown in SEC filings. Cohen and Milstein usually take these cases on contingency. Thus, it is rational to assume it HAS been taken on contingency, since this is a HUGE lawsuit.
"In January 2016 Black became an independent director of NWBO to investigate the market manipulation of the company's stock by the hedge fund "wolfpack". The wolfpack and others use naked shorting of stock to drive promising young biotechs toward bankruptcy or to the point where they need to raise capital at extremely low valuations from the wolfpack themselves", as was stated in an Alchetron news article.
NWBO stated in a PR
"It is exciting to see the potential of the DCVax personalized immune therapies being developed by NW Bio for a wide range of cancers. I look forward to utilizing my expertise in helping the Company protect its technology and operations."
So when the lawsuit came 2022, and the plaintiff say they have +6 years of evidence against MM and their spoofing, it is rational to believe, THAT was Cofer Blacks job.
A Nature journal preprint is on its way regarding the results of the DCvax-L and poly-iclc trial.
MHRA stated about confirmatory efficacy trial
Although each biosimilar development needs to be evaluated on a case by case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach.
FDA states in its guidance documents outline how biosimilars may be approved based on pharmacokinetic (PK) data and PD biomarker data without a comparative clinical efficacy study. Reliance on PK and PD data allows for shorter and less costly clinical studies that can often be conducted in healthy participants
Let's look at facts about companies Revimmune SAS, Ltd, Inc
Linda Powers director in US and UK and in full control. Revimmune trials with Interleukin-7 back more than a decade gets PR'ed as Revimmune Inc. http://Revimmune.com say Maryland Bethesda is head office. Head office address is same address as Northwest Bio Inc and Toucan Capital. Revimmune is assignee on combo patent from 2014. Interleukin-7 also called IL-7 is in many claims on the combo patent. Before 2012 it was called CYT-107 after the company Cytheris. Mac Cheever was working with it. He joined NWBO SAB in 2016.
Revimmune Ltd dormant company but just been confirmed, that "its intended future activities are lawful" meaning ...
[Suppressed Image]
Industry Codes used
[Suppressed Image]
$NWBO is in control of NWBO Limited since January 19th. 2024. Linda Powers ASSIGNED control to NWBO Inc.
3 months ago!!!
Northwest Biotherapeutics Limited and Revimmune Inc shares a funny same address.
J Kelly Ganjei from AmplifyBio and being on the combo patent and Philippe Pire from Advent Bioservices are "attached".
[Suppressed Image]
[Suppressed Image]
Linda Powers and Mark Lowdell ownes a company called Novamune LTD.
[Suppressed Image]
[Suppressed Image]
On April 2 a compulsory strike-off was sent and supposedly Novamune had two months to respond. On April 25, the government issued a formal notice already on discontinuing the strike-off notice.
Mark Lowdell is a consultant to Inmune Bio. Turns out he is ALSO on the SAB board of NWBO.
[Suppressed Image]
But NWBO have not disclosed him being so!
J Kelly Ganjei, the guy having worked for Linda Powers at Toucan, who is on the combo patent, who is CEO of AmplifyBio is also on the board of Inmune Bio
Phil Parry who have been head of engineering at Roche and Autolomous just hired at Advent Bioservice. A step down or step up?
noch ausführlicher:
https://investorshub.advfn.com/boards/read_msg.aspx?message_…
neues von UCLA
https://www.uclahealth.org/news/article/new-california-insti…
klingt alles so, als ob in erster Linie DCVax beschrieben wird, 😜
https://www.uclahealth.org/news/article/new-california-insti…
klingt alles so, als ob in erster Linie DCVax beschrieben wird, 😜
TST bezgl GermanCol
German Col hatte das Geld für IBRX gebraucht! IBRX - sehr interessant - hat eine Cancer-Lösung für Blasenkrebs und viele weitere Krebsarten (später - demnächst lol)
Gestern um 50% gestiegen. Supertiming für GC. Er wird evtl. die gewinne wieder einvestieren in nwbo - hat selbst noch eine position in northwest! (da IBRX ähnlich gute pipeline hat, ist dies aber meiner meinung nach nicht nötig - wobei ich nwbo "noch e bisserl "POTENTIALER" lol einstufe)
ICH bin selbst seit ca. 2 monaten mit neuem Geld (kleinerem Betrag) in IBRX (auch erstmal ins minus gegangen) und hätte NIE den mut gehabt mein NWBO zum großen teil aufzulösen. DAS IST EBEN DAS DILEMMA - wenn ich/wir hellseher wären, hätten wir ganz anders gehandelt, (raus vor dem großem preisverfall - jetzt langsam wieder rein . . . . )
schönes Wochende dir TST
(und all die , die noch ab und zu hier lesen)
German Col hatte das Geld für IBRX gebraucht! IBRX - sehr interessant - hat eine Cancer-Lösung für Blasenkrebs und viele weitere Krebsarten (später - demnächst lol)
Gestern um 50% gestiegen. Supertiming für GC. Er wird evtl. die gewinne wieder einvestieren in nwbo - hat selbst noch eine position in northwest! (da IBRX ähnlich gute pipeline hat, ist dies aber meiner meinung nach nicht nötig - wobei ich nwbo "noch e bisserl "POTENTIALER" lol einstufe)
ICH bin selbst seit ca. 2 monaten mit neuem Geld (kleinerem Betrag) in IBRX (auch erstmal ins minus gegangen) und hätte NIE den mut gehabt mein NWBO zum großen teil aufzulösen. DAS IST EBEN DAS DILEMMA - wenn ich/wir hellseher wären, hätten wir ganz anders gehandelt, (raus vor dem großem preisverfall - jetzt langsam wieder rein . . . . )
schönes Wochende dir TST
(und all die , die noch ab und zu hier lesen)
alles korrekt was Du sagst.
die i hubber machen sich ja selbst das leben schwer, indem sie überzogene und völlig irreale zeitrahmen proklamieren.
beispiele, in den nächsten wochen . . . . .
ende april / mai / juni
dadurch kommt natürlich (unnötiger) frust auf
zusätzlich zu dem NATÜRLICHEN frust den wir alle haben,
weil alles so lange dauert
weil wir verwässert werden (völlig normal für prerevenue pharma)
zu extrem niedrigen aktienkurs
der immer noch weiter fällt
und damit "alles noch schlimmer (verwässerung, preis deflation usw.) wird"
* schlimmer, da aktienkurs weiter "runter" manipuliert wird, durch spoofing, FUD und vielem mehr.
DESHALB: schei....aktie? schei...firma? schei...management? schei....Linda Powers? schei....NWBO?
NEIN
scheiß hedgefunds, criminals, spoofer, you name it
die i hubber machen sich ja selbst das leben schwer, indem sie überzogene und völlig irreale zeitrahmen proklamieren.
beispiele, in den nächsten wochen . . . . .
ende april / mai / juni
dadurch kommt natürlich (unnötiger) frust auf
zusätzlich zu dem NATÜRLICHEN frust den wir alle haben,
weil alles so lange dauert
weil wir verwässert werden (völlig normal für prerevenue pharma)
zu extrem niedrigen aktienkurs
der immer noch weiter fällt
und damit "alles noch schlimmer (verwässerung, preis deflation usw.) wird"
* schlimmer, da aktienkurs weiter "runter" manipuliert wird, durch spoofing, FUD und vielem mehr.
DESHALB: schei....aktie? schei...firma? schei...management? schei....Linda Powers? schei....NWBO?
NEIN
scheiß hedgefunds, criminals, spoofer, you name it
13.10.23 · PR Newswire (engl.) · Northwest Biotherapeutics |
25.09.23 · Accesswire · Northwest Biotherapeutics |